BIIB VS IQV Stock Comparison
Performance
BIIB74/100
74/100
BIIB returned -15.64% in the last 12 months. Based on SPY's performance of -20.65%, its performance is above average giving it a score of 74 of 100.
IQV91/100
91/100
IQV returned -8.00% in the last 12 months. Based on SPY's performance of -13.62%, its performance is above average giving it a score of 91 of 100.
Analyst Price Targets
BIIB73/100
73/100
32 analysts offer 12-month price targets for BIIB. Together, they have an average target of 294.73, the most optimistic target put BIIB at 405 within 12-months and the most pessimistic has BIIB at 209.
IQV69/100
69/100
17 analysts offer 12-month price targets for IQV. Together, they have an average target of 277.18, the most optimistic target put IQV at 320 within 12-months and the most pessimistic has IQV at 235.
Sentiment
BIIB70/100
70/100
BIIB had a bullish sentiment score of 70.25% across Twitter and StockTwits over the last 12 months. It had an average of 66.53 posts, 492.48 comments, and 835.41 likes per day.
IQV
"Sentiment" not found for IQV
Technicals
BIIB14/100
14/100
BIIB receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.
IQV75/100
75/100
IQV receives a 75 of 100 based on 14 indicators. 10 are bullish, 3 are bearish.
Earnings
BIIB61/100
61/100
BIIB has missed earnings 2 times in the last 20 quarters.
IQV100/100
100/100
IQV has missed earnings 0 times in the last 20 quarters.
Profit
BIIB64/100
64/100
Out of the last 20 quarters, BIIB has had 19 profitable quarters and has increased their profits year over year on 6 of them.
IQV88/100
88/100
Out of the last 20 quarters, IQV has had 19 profitable quarters and has increased their profits year over year on 12 of them.
Volatility
BIIB40/100
40/100
BIIB has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.
IQV49/100
49/100
IQV has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.
All score calculations are broken down here to help you make more informed investing decisions
Biogen Inc. Common Stock Summary
Nasdaq / BIIB
Healthcare
Drug Manufacturers - General
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
IQVIA Holdings Inc. Summary
New York Stock Exchange / IQV
Healthcare
Medical - Diagnostics & Research
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare BIIB to other companies in the same or a similar industry.